The European Medicines Agency granted orphan drug designation to PhaseRX (Nasdaq: PZRX) for its PRX-OTC to treat ornithine transcarbyamylase deficiency. Shares of the biopharmaceutical soared 67 cents to close at $1.91.
PhaseRx receives orphan drug designation
April 24, 2017 at 17:09 PM EDT
